Daxxify (daxibotulinumtoxinA-lanm)

The acetylcholine release inhibitor and neuromuscular blocking drug DAXXIFY is prescribed for the following conditions in adult patients: 

• Temporary relief in the appearance of moderate to severe glabellar lines associated with corrugator and/or procerus muscle activation.
  
• treatment for adult individuals with cervical dystonia.

• Glabellar Lines: An intramuscular injection of 0.1 mL (8 Units) at five different places should be used as the suggested dosage, for a total of 40 Units. For cervical dystonia: An intramuscular administration of 125–250 units, distributed across the impacted muscles, is the indicated dose.
  

• Spread of Toxin Effect: Botulinum toxin effects may extend beyond the injection site, causing symptoms like muscle weakness, blurred vision, and breathing difficulties. These reactions, reported hours to weeks after injection, can be life-threatening. Immediate medical attention is crucial if symptoms occur, especially in children treated for spasticity.
  
• Lack of Interchangeability: DAXXIFY’s potency units are specific and not interchangeable with other botulinum toxin products. The units cannot be compared, emphasizing the need for consistent use.
  
• Serious Adverse Reactions with Unapproved Use: Serious reactions, including weakness and dysphagia, occurred with unapproved botulinum toxin use. Caution is advised, especially in patients with pre-existing conditions.
  
• Hypersensitivity Reactions:Serious hypersensitivity reactions, though rare, require immediate discontinuation. Caution is urged in patients with known hypersensitivity to botulinum toxin or its components.
  
• Cardiovascular System: Reports of cardiovascular events post-botulinum toxin administration emphasize caution in patients with pre-existing cardiovascular disease.
  
• Pre-Existing Neuromuscular Disorders: Patients with neuromuscular disorders may experience increased neuromuscular compromise, necessitating close monitoring after treatment.
  
• Dysphagia and Breathing Difficulties: Dysphagia and breathing difficulties, potential complications of botulinum toxin treatment, require attention, especially in patients with compromised respiratory function.
  
• Pre-existing Conditions at the Injection Site: Caution is needed in patients with facial alterations, asymmetry, or scarring. Attention to muscle weakness and glabellar line reduction is crucial.
  
• Ophthalmic Adverse Reactions: Dry eye and corneal disorders have been reported. Persistent symptoms warrant consultation with an ophthalmologist.
  

If you are considering the import of Daxxify (daxibotulinumtoxinA-lanm)  to India, please be aware that Daxxify can be imported by patients or government hospitals solely in the name of the patients. The following documentation is essential for the successful import of this medication:

Required Documentation for Import:

• A valid prescription from a qualified medical practitioner.
  
• Diagnostic reports of the patient.
  
• Government-issued identification proof for the patient, as recognized by the Government of India.

Order Confirmation Process:

The order for Daxxify (daxibotulinumtoxinA-lanm) will be confirmed upon the receipt of the following documents:

• A valid prescription from a qualified doctor.
  
• An import permit, if applicable.

Availability of Daxxify in India: 

Daxxify (daxibotulinumtoxinA-lanm) is classified as a prescription pharmaceutical drug. Consequently, it legally requires a medical prescription to be dispensed. Indian Pharma Network (IPN) specializes in facilitating the import of cancer medicines through named patient supply (NPS), ensuring transparency and authenticity by sourcing from reputable suppliers in the USA, Canada, Europe, and Australia.

Daxxify can be made accessible to patients, doctors, and hospitals in various cities across India, including but not limited to Mumbai, Kolkata, Hyderabad, Chennai, Ahmedabad, Delhi, Bangalore, Srinagar, Jammu, Jaipur, Chandigarh, Ludhiana, Noida, Gurgaon, Lucknow, and Pune. To confirm an order, a valid prescription from a doctor and an import permit will be required.

IPN (Indian Pharma Network) is dedicated to facilitating the supply of Daxxify (prescription medicines) to locations both within India and worldwide, while adhering to relevant legal requirements.

Our commitment lies in assuring quality and timely delivery to meet the healthcare needs of patients and medical professionals across the globe.

Indian Pharma Network is proficient in sourcing Daxxify (daxibotulinumtoxinA-lanm) from around the world and ensuring efficient delivery to patients. We provide worldwide access to the best available treatments and expedite prescription dispensing and delivery, with all prescriptions being dispensed and scrutinized by registered pharmacists before dispatching them to the patient’s address, exclusively from New Delhi, India.